Pfizer says FDA okays arthritis drug

Get the weekly rundown
Sign up to receive our weekly BizBuzz newsletter

Pfizer says the Food and Drug Administration approved its rheumatoid arthritis pill Xeljanz, seen as potential big seller for the company.

Pfizer Inc. says the FDA approved Xeljanz as a treatment for moderate to severe rheumatoid arthritis in patients who can't take methotrexate or haven't been helped by it. Xeljanz is intended to slow the progression of the disease. The approval comes about two weeks sooner than expected.

Xeljanz, or tofacitinib, is the first rheumatoid arthritis treatment from a new class of pain medications called JAK inhibitors. The drugs interfere with enzymes that contribute to tissue inflammation.

- Associated Press

READER COMMENTS

Loading comments...
Hide Comments

Stories that may interest you

Boat sales, revenue up since Connecticut lowered tax

Effective July 1, 2018, the sales tax changed from 6.35 percent to 2.99 percent.


Mystic Aquarium offering free admission for EBT cardholders and three guests

Mystic Aquarium has announced that it will extend and revamp its program for Connecticut Electronic Benefit Transfer cardholders by now offering free admission to cardholders and up to three of their guests through Dec. 31.


Mohegan Sun offering discounts for military personnel

More than 40 casino shops and dining locations participating in year-round program


Mystic Aquarium to celebrate Long Island Sound Day on Saturday

Mystic Aquarium will a day of hands on activities on Saturday from 10 a.m. to 2 p.m. in recognition of Long Island Sound Day and to support the health of the estuary.

TRENDING

PODCASTS